• Importance of developability during candidate selection
• Getting the right molecule through clinical process
• In-use stability challenges of low dose products
• Formulating low dose products
  

It’s vital to ensure appropriate assessment of molecules at the early research phase is carried out to risk mitigate movement into the development phase. This ensures the best risk of success with minimal usage of resources and finances. This presentation will highlight the procedures for assessing developability and also showcases the challenges associated with administering low concentration biologics.

Shahid Uddin

Senior Director Formulation Development and Laboratory Operations CMC

Immunocore